We serve Chemical Name:fmoc-d-leucinol CAS:215178-41-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:fmoc-d-leucinol
CAS.NO:215178-41-9
Synonyms:FMOC-(2R,3R)-2-AMINO-3-METHYL-1-PENTANOL;N-(9-FLUORENYLMETHOXYCARBONYL)-D-LEUCINOL;REF DUPL: Fmoc-D-leucinol;FMOC-D-LEU-OL;(R)-(9H-fluoren-9-yl)methyl 1-hydroxy-4-methylpentan-2-ylcarbamate
Molecular Formula:C21H25NO3
Molecular Weight:339.42800
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:525.204ºC at 760 mmHg
Density:1.149g/cm3
Index of Refraction:1.576
PSA:58.56000
Exact Mass:339.18300
LogP:4.32300
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like FMOC-(2R,3R)-2-AMINO-3-METHYL-1-PENTANOL chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(R)-(9H-fluoren-9-yl)methyl 1-hydroxy-4-methylpentan-2-ylcarbamate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(R)-(9H-fluoren-9-yl)methyl 1-hydroxy-4-methylpentan-2-ylcarbamate Use and application,N-(9-FLUORENYLMETHOXYCARBONYL)-D-LEUCINOL technical grade,usp/ep/jp grade.
Related News: First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s. fmoc-d-leucinol manufacturer It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance. fmoc-d-leucinol supplier Physiologically relevant interactions with test molecules or protein ligands can be identified with high sensitivity and specificity. fmoc-d-leucinol vendor ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy. fmoc-d-leucinol factory First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s.
